Bone marrow stem cells may be obtained from the transplant recipient (autologous HCT) or from a donor (allogeneic HCT). Hematopoietic cell transplantation (HCT) is a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of drugs with or without whole body radiotherapy. However, cancer recurs in most women, and they die of the disease because chemotherapy drug resistance leads to uncontrolled cancer growth. Use of platinum and taxanes has improved progression-free survival and overall survival in advanced disease to between 16 and 21 months and 32 and 57 months, respectively. Most ovarian cancer patients present with widespread disease, and the National Cancer Institute Surveillance, Epidemiology and Results Program reported a 46.5% five-year survival for all cases between 20.Ĭurrent management for advanced epithelial ovarian cancer is cytoreductive surgery with chemotherapy.Īpproximately 75% of patients present with International Federation of Gynecology and Obstetrics stage III to IV ovarian cancer and are treated with paclitaxel plus a platinum analogue, the preferred regimen for the newly diagnosed advanced disease. For 2016, new cases and deaths from ovarian cancer in the United States were estimated at 22,280 and 14,240, respectively. Epithelial ovarian cancer is the fifth most common cause of cancer death in women. Several types of malignancies can arise in the ovary, and epithelial carcinoma is the most common. Hematopoietic stem cells are infused to restore bone marrow function after cytotoxic doses of chemotherapeutic agents with or without whole body radiotherapy. Use of hematopoietic cell transplantation (HCT) has been investigated for treatment of patients with epithelial ovarian cancer. This policy explains why it is considered to be investigational.Ĭondition Investigational Advanced stage epithelial ovarian cancer These transplants are considered investigational. Hematopoietic stem cell transplants are sometimes given to patients who have epithelial ovarian cancer. If the stem cells come from the patient herself before her high dose chemotherapy is given, it is called an autologous stem cell transplant. If the stem cells are harvested from another person, it is called an allogeneic stem cell transplant. The stem cells can also be harvested from the patient herself before she is given any high dose chemotherapy. In a hematopoietic stem cell transplant, stem cells can be taken from a donor’s bone marrow, peripheral blood, or from a newborn baby’s umbilical cord blood or placenta shortly after the baby was delivered. Hematopoietic stem cells are cells that form within the bone marrow and can become many different types of blood cells. Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer S2150 Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications including: pheresis and cell preparation/storage marrow ablative therapy drugs, supplies, hospitalization with outpatient follow-up medical/surgical, diagnostic, emergency, and rehabilitative services and the number of days of pre and post transplant care in the global definition S2142 Cord blood-derived stem-cell transplantation, allogeneic S2140 Cord blood harvesting for transplantation, allogeneic Autologous and allogeneic hematopoietic cell transplants are considered investigational to treat advanced stage epithelial ovarian cancer.ģ8232 Bone marrow harvesting for transplantation autologousģ8240 Hematopoietic progenitor cell (HPC) allogeneic transplantation per donorģ8241 Hematopoietic progenitor cell (HPC) autologous transplantation
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |